Clinical Evaluation of Tavocept to Decrease Diuresis Time and Volume in Dogs with Bladder Cancer Receiving Cisplatin

Journal of Veterinary Internal Medicine
C HenryF Hausheer

Abstract

Transitional cell carcinoma is the most common bladder cancer of dogs. Cisplatin combined with piroxicam provides superior response rates, but unacceptable rates of nephrotoxicity. Tavocept is a chemoprotectant that has mitigated cisplatin toxicity and decreased the required infusion/diuresis volume in clinical trials in humans. We hypothesized that Tavocept would decrease diuresis volume and time and facilitate safe administration of a cisplatin/piroxicam protocol to dogs with bladder cancer. Secondary objectives were to compare response rate and survival times to an historical comparator group treated without Tavocept. Fourteen client-owned dogs were prospectively enrolled. Tumor volume was measured by computed tomography at days 0, 42, and 84. Dogs received combination Tavocept/cisplatin with a shortened diuresis protocol. A total of 4 doses was planned, with concurrent administration of piroxicam. Serial biochemical analyses were evaluated for azotemia. A 90-minute infusion/diuresis time was used for all dogs. Three dogs (21%) had concurrent increases in serum creatinine (>2.0 mg/dL) and BUN (>42 mg/dL) concentrations; 2 of these dogs were isosthenuric. This frequency of nephrotoxicity is significantly less (P = 0.0406) tha...Continue Reading

References

Jul 1, 1994·Journal of Veterinary Internal Medicine·D W KnappT Kuczek
Feb 12, 1998·Journal of Veterinary Internal Medicine·R ChunC M Han
May 30, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J Lokich, N Anderson
May 15, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E BovenW J F van der Vijgh
Jul 11, 2003·The Veterinary Clinics of North America. Small Animal Practice·Carolyn J Henry
Aug 2, 2003·Clinical Pharmacology and Therapeutics·Miranda VerschraagenWim J F van der Vijgh
Apr 15, 2004·British Journal of Cancer·M VerschraagenW J F van der Vijgh
Jun 7, 2007·Journal of the National Cancer Institute·Andrea ArdizzoniUNKNOWN CISCA (CISplatin versus CArboplatin) Meta-analysis Group
Oct 6, 2007·Journal of the American Veterinary Medical Association·Shawna N GreeneDeborah W Knapp
Jun 1, 2005·Veterinary and Comparative Oncology·P A BoriaD W Knapp
Aug 29, 2009·Cancer Chemotherapy and Pharmacology·Frederick H HausheerAulma R Parker
May 5, 2010·Cancer Chemotherapy and Pharmacology·F H HausheerH Kochat
May 18, 2010·Cancer Chemotherapy and Pharmacology·Noriyuki MasudaMasahiro Fukuoka
Mar 9, 2011·Bulletin du cancer·Coralie MoncharmontNicolas Magné
Oct 12, 2011·Journal of the American Veterinary Medical Association·Sarah K McMillanDeborah W Knapp
Nov 19, 2011·Journal of Veterinary Internal Medicine·E J ArnoldD W Knapp
Oct 9, 2012·Seminars in Oncology·Andrei S PuryskoBrian R Herts
Dec 12, 2012·Journal of the American Veterinary Medical Association·Sarah K McMillanLarry G Adams
May 21, 2013·Journal of the American Veterinary Medical Association·Diane R SchremppDeborah W Knapp

❮ Previous
Next ❯

Citations

Jun 5, 2019·Journal of Comparative Pathology·S de BrotN P Mongan
Dec 4, 2021·Frontiers in Bioengineering and Biotechnology·Sen LiuWei Ye

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.